An Analysis of the Therapeutic Effectiveness Repaglinide in the Treatment of Type II Diabetes Mellitus

Objective:To analyze the therapeutic effectiveness of repaglinide in the treatment of Type Ⅱ diabetes mellitus. Method:40 patients with Type Ⅱ diabetes mellitus meeting the 1985 WHO diagnosis criteria were treated with repaglinide. Patients were given each 0.5 mg of repaglinide PO 15 min before each meal. A supplementary dose was administered before an additional meal. If a meal was missed, the corresponding dose was omitted. Fasting blood glucose and 2 h postprandial blood glucose were determined fortnightly. The dose of repaglinide was increased to 1.0～1.5 mg before meal if blood glucose had not been well controlled. The observation lasted 12 weeks. Levels of blood lipid, glucose and insulin before and after the treatment were compared. Results:A remarkable fall in the levels of fasting and 2 h postprandial blood glucose, glycosylated hemoglobin and tyiglyceride was demonstrated ( P 0.01) after the treatment. In the meantime, the level of 2 h postprandial insulin rose significantly ( P 0.05). Conclusion:Repaglinide is an effective remedy in the treatment of diabetes mellitus. The incidence of adverse reactions including hypoglycemia is low. It may improve the diabetics' compliance with treatment.